GLI3 and breast cancer: In the different breast cancer cell lines assessed by Kurebayashi et al. (2017), including tumor stem cell lines, GANT61 was found to significantly decrease the levels of GLI1 and GLI2 expression, but not GLI3, in a dose-dependent manner [16].